Li P, Ma B, Gong S, Zhang X, Li W.
Surg Endosc. 2019 Jun 24.
Endoscopic sleeve gastroplasty (ESG) is a minimally invasive, effective, and safe technique for weight loss intervention. Since a
relatively small number of cases were present in previous studies, this study aimed to elucidate the efficacy and safety of ESG.
Relevant publications were identified through searching PubMed, EMBASE, Cochrane, and Web of Science before March 1,
2019. The percentage of total body weight loss (%TBWL), percentage of excess weight loss (%EWL), and the adverse event rate
in each follow-up session were extracted, pooled, and analyzed. Forest plots were graphed based on random effects models.
A total of 1542 patients from nine studies were eligible for analysis. The pooled results of %TBWL at 1, 3, 6, and 12 months
were 8.78% (p = 0.000), 11.85% (p = 0.000), 14.47% (p = 0.024), and 16.09% (p = 0.063), respectively. The pooled results
of %EWL at 1, 3, 6, and 12 months were 31.16% (p = 0.000), 43.61% (p = 0.000), 53.14% (p = 0.000), and 59.08% (p =
0.015), respectively. Finally, the pooled rate of mild adverse events was 72% (p < 0.01), and the pooled estimate of severe
adverse events was only 1% (p = 0.08).
Although the conventional surgical sleeve gastrectomy is the gold standard for bariatric surgery, ESG could be a promising
minimally invasive alternative for treating obesity with satisfactory efficacy and low risk.